A5080937394- Pharmacy and Medical Practices
- Cancer Treatment and Pharmacology
- Colorectal Cancer Treatments and Studies
- Hepatocellular Carcinoma Treatment and Prognosis
- Lung Cancer Treatments and Mutations
- Pharmaceutical Practices and Patient Outcomes
- Gastric Cancer Management and Outcomes
- Advanced Breast Cancer Therapies
- Gastrointestinal Tumor Research and Treatment
- Neutropenia and Cancer Infections
- Safe Handling of Antineoplastic Drugs
- HER2/EGFR in Cancer Research
- Ginkgo biloba and Cashew Applications
- Cancer-related Molecular Pathways
- Nausea and vomiting management
- Chemotherapy-related skin toxicity
- Liver Disease Diagnosis and Treatment
- Pharmacological Effects of Natural Compounds
- Blood disorders and treatments
- Anesthesia and Pain Management
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Colorectal Cancer Surgical Treatments
- Drug-Induced Hepatotoxicity and Protection
- Sympathectomy and Hyperhidrosis Treatments
- Multiple and Secondary Primary Cancers
Ogaki Municipal Hospital
2016-2024
Abstract The most common toxicities associated with cyclin‐dependent kinase (CDK) 4/6 inhibitor therapy include decreased leukopenia and neutropenia due to the inhibition of CDK6 leukocyte neutrophil precursors in bone marrow. These hematological are more commonly observed palbociclib administration than abemaciclib administration, which is approximately 13 times selective against CDK4 CDK6. Thus, even though both successfully inhibit CDK4/6, side effects differ differences selectivity....
Introduction: Anaplastic lymphoma kinase (ALK) has been to be involved in the uptake and regulation of dopamine 2 receptor (D2R), a G protein-coupled expressed various brain regions. Therefore, it is crucial understand relationship between ALK inhibitors seizures an important issue. This study investigated seizures. Methods: through disproportionality analysis using US Food Drug Administration (FDA) Adverse Event Reporting System (FAERS). The target drugs were crizotinib, ceritinib,...
Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs), including gefitinib, erlotinib and afatinib are standard first-line treatments for EGFR gene mutation-positive non-small cell lung cancer. The present study aimed to compare the cost-effectiveness of using erlotinib, or gefitinib. safety EGFR-TKIs was also investigated. Expected costs were calculated based on data from patients with advanced non-small-cell cancer who treated afatinib. Literature collected obtain...
Introduction When rapid feedback to physicians must be provided, e.g. monitoring therapy with the oral anticoagulant warfarin or providing therapeutic support for patients undergoing cancer chemotherapy, involvement of pharmacists is required outpatients. We launched a pharmacist outpatient service taking anti-cancer agents. evaluated role and usefulness these monotherapy Methods Data regarding prescription recommendations were collected from drug management guidance records 154 who...
Regorafenib and trifluridine/tipiracil combination tablet regimens are standard third-line or later treatments for advanced recurrent colorectal cancer with no significant difference in efficacy. The present study aimed to compare the cost-effectiveness of using regorafenib vs. tablet. expected cost was calculated based on data from patients who were treated median survival time (MST) CORRECT RECOURSE used evaluate therapeutic efficacy regimens. ratio MST two per patient regimen ¥705,330.3...
S-1 adjuvant chemotherapy is an outpatient treatment for gastric cancer. To evaluate the role of pharmacist service in increasing medication adherence and reducing adverse events associated with S-1, present study retrospectively analyzed prescription recommendations from pharmacists to physicians persistence rate use patients A total 40 subjects who utilized between November 2014 March 2016 comprised group; 94 underwent cancer September 2012 October 2014, but not as outpatients, control...
Background: Olaparib and niraparib (poly adenosine diphosphate [ADP]-ribose polymerase [PARP] inhibitors) have significant antitumor action in patients with ovarian cancer.However, the incidence of nausea vomiting among on these drugs clinical trials is rather high.There are no guidelines antiemetic treatment for caused by oral anticancer agents.This study aimed to investigate PARP inhibitors actual situation therapy gynecologic cancer.Methods: Patients cancer who were scheduled receive...
Appropriate adverse event (AE) management and maintenance of therapeutic intensity are necessary to achieve benefits CDK4/6 inhibitors (palbociclib abemaciclib) in hormone receptor-positive, HER2-negative metastatic/recurrent breast cancer.
Lenvatinib (LEN), a multitarget tyrosine kinase inhibitor, is standard therapeutic agent for hepatocellular carcinoma, but the high incidence of adverse events (AEs) related to LEN treatment often necessitates discontinuation. The present study aimed clarify efficacy and tolerability modified dosing methods, such as alternate-day dosing, necessitated by AEs LEN. A total 66 patients who received at Ogaki Municipal Hospital (Ogaki, Japan) between April 2018 January 2022 were retrospectively...
Atezolizumab/bevacizumab (Atez/BV) and lenvatinib (LEN) are the recommended first-line treatments for patients with unresectable hepatocellular carcinoma (HCC). Previous reports have suggested that tolerability therapeutic efficacy of LEN could be enhanced by modifying its administration method. Therefore, this study compared safety Atez/BV, standard therapy (standard LEN), modified (modified LEN).
Atezolizumab plus bevacizumab (Atez/BV) as first‑line therapy and lenvatinib (LEN) second‑line are the recommended treatments for patients with unresectable hepatocellular carcinoma. Adverse immune events caused by checkpoint inhibitors (such Atez) generally only occur several months after administration; therefore, potential influence of treatment on is not clear. The present study investigated safety LEN (2nd LEN) comparing adverse (AEs) 2nd Atez/BV liver cancer, those (1st LEN). Patients...
Lenvatinib (LEN) is the standard treatment for hepatocellular carcinoma (HCC). In clinical practice, gastrointestinal (GI) symptoms such as fatigue and loss of appetite often lead to dose reduction or discontinuation. This study aimed identify predictors patients who will experience discontinuation owing GI during LEN HCC.
The cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor palbociclib is associated with a high incidence of neutropenia. Treatment continuation using the standard dosing schedule (3 consecutive weeks oral administration followed by 1-week off-treatment: 3/1 schedule) can be difficult other schedules have been previously adopted. We aimed to investigate whether alternative used effectively continue palbociclib.
Introduction Pegfilgrastim is a PEGylated formulation of filgrastim with long half-life. It highly convenient and less burdensome for patients. However, white blood cell count may temporarily increase after administration; in particular, leukocyte overshoot be observed. The present study retrospectively examined the incidence timing pegfilgrastim administration. Patients methods Fifty-five patients (118 occasions pegfilgrastim) were evaluated. Leukocyte was defined as ≥10,000/mm 3 exceeding...
A pharmacist outpatient service for patients receiving monotherapy with oral anticancer drugs aims to improve safety and medication continuation through pre-examination interviews. We assess adherence monitor chemotherapy-induced adverse events by referring patientsʼ complaints of symptoms their medical diaries. In addition, “unused prescribed medicines” can also be a useful information resource. However, unused medicines are becoming large-scale problem in Japan, thus leading lower...
The present study aimed to determine the effect of timing treatment discontinuation on prognosis patients with advanced and recurrent gastric cancer chemotherapy. Between July 2014 March 2017, 127 who underwent chemotherapy for at Ogaki Municipal Hospital (Ogaki, Japan) were examined. To factors associated survival, multivariate analysis using Cox proportional hazards model, hazard ratios their 95% confidence intervals (95% CI) calculated. reasons last-line last hospitalization prior...
In this study, we aimed to detect nausea early, reduce and maintain the QOL of patients administered adjuvant chemotherapy with S-1. Therefore, determined whether PONV (postoperative vomiting) is a risk factor for in treated S-1 chemotherapy. From January 2017 April 2018, 75 who underwent at Ogaki Municipal Hospital were evaluated. Risk factors examined by multivariate analyses. Twenty-three (30.7％) experienced nausea. was not However, sex (female; odds ratio: 3.98, 95％ CI: 1.11 w- 14.20, P...
This study clarifies the utility of guidance on original nutrition table provided to patients undergoing monotherapy with oral anticancer agents. A satisfaction survey, using a questionnaire, was conducted. Nutritional indicators (weight loss and albumin) treatment completion rate were compared for receiving S-1 adjuvant chemotherapy at Ogaki Municipal Hospital before (from February 2017 2018, 68 cases) after March 2018 August 2019, 37 creation table. 83.0％ (83/100) had high overall table,...
This study aimed to clarify the situation of use health foods by patients and level satisfaction in order make information on cases where undergoing cancer medication therapy foods. Between May 7, 2018 June 29, 2018, we conducted a questionnaire survey with progressive who were chemotherapy at Ogaki Municipal Hospital. In addition, multivariate analysis using those not. The items included objectives use, product effectiveness satisfaction, QOL. rate food was 81/281 (29.5%). primary were, "to...